At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 110 enrolled
Drug / intervention
Benralizumab +1 morebiological
Likely dose
Benralizumab 1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563, A Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, on Asthma Control Following Acute Exacerbations in Adults
In Brief
A Phase 2 clinical trial evaluating Placebo and Benralizumab for Asthma. Completed, enrolled 110 participants across 11 sites in 2 countries.
Detailed Summary
The study will evaluate the effect of two intravenous dose regimens of benralizumab (MEDI-563) on the proportion of adult subjects with asthma exacerbations who required an urgent healthcare visit for treatment of an acute asthma exacerbation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartFeb 2009
Primary CompletionDec 2010
Study CompletionMar 2011
TodayJul 2026
First PostedOct 7, 2008
Enrollment StartFeb 2, 2009
Primary CompletionDec 17, 2010
Study CompletionMar 10, 2011
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.7 years ago
Interventions
Placeboother
A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
Benralizumabbiological
A single dose of benralizumab (MEDI-563) 0.3 or 1 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.